Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
13F holders, Q2 2026 (June 30)4holders −3
0new positions
3sold out
$1.11avg. 13F price*
At the end of Q2 2026, 4 institutions reported holding Bridgebio Pharma Inc. (bbio 2.25 02/01/29) in their 13F filings, down 3 from Q1 2026. 0 opened new positions and 3 sold out. The largest holders were Bank of New York Mellon Corp ($1.1M), Sei Investments Co. ($417K) and Oppenheimer Asset Management Inc. ($121K).
- Company
- Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
- CUSIP
- 10806XAD4
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $9.6M |
All 13F filers, Q1 2026 → Q2 2026: 4,000 shares bought and 8,596,000 shares sold, net −8,592,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Bank of New York Mellon Corp | 0.00% | No change | 1,000,000 | $1.1M |
| Sei Investments Co. | 0.00% | No change | 377,000 | $417K |
| Oppenheimer Asset Management Inc. | 0.00% | Add +3.8% | 109,000 | $121K |
| Stephens Inc. | 0.00% | Reduce -3.0% | 32,000 | $35K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.25 02/01/29) the manager owns.